CompletedNCT00579280
Quetiapine, divalproex, or placebo for anxiety in bipolarity
About this title
Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD
Read the official source — NCT00579280Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Palo Alto and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 224
- Sponsor
- University of South Florida
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00579280
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Palo Alto · Tampa · Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of South Florida, a university.
Did this study involve medication?
Yes. The study involved medication, including quetiapine SR, divalproex sodium ER and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
